Inhibitors targeting on cell wall biosynthesis pathway of MRSA.
Methicillin resistant Staphylococcus aureus (MRSA), widely known as a type of new superbug, has aroused world-wide concern. Cell wall biosynthesis pathway is an old but good target for the development of antibacterial agents. Peptidoglycan and wall teichoic acids (WTAs) biosynthesis are two main processes of the cell wall biosynthesis pathway (CWBP). Other than penicillin-binding proteins (PBPs), some key factors (Mur enzymes, lipid I or II precursor, etc.) in CWBP are becoming attractive molecule targets for the discovery of anti-MRSA compounds. A number of new compounds, with higher affinity for PBPs or with inhibitory activity on such molecule targets in CWBP of MRSA, have been in the pipeline recently. This review concludes recent research achievements and provides a complete picture of CWBP of MRSA, including the peptidoglycan and wall teichoic acids synthesis pathway. The potential inhibitors targeting on CWBP are subsequently presented to improve development of novel therapeutic strategies for MRSA.
National Reference Laboratory of Veterinary Drug Residues and MOA Key Laboratory for the Detection of Veterinary Drug Residues in Foods, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei 430070, China.
Haihong
H
Hao
Guyue
G
Cheng
Menghong
M
Dai
Qinghua
Q
Wu
Zonghui
Z
Yuan
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D053898:Biosynthetic Pathways / Q000187:drug effects; D002473:Cell Wall / Q000187:drug effects* / Q000378:metabolism*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000378:metabolism*; D010457:Peptidoglycan / Q000378:metabolism; D013682:Teichoic Acids / Q000378:metabolism
D000900:Anti-Bacterial Agents; D010457:Peptidoglycan; D013682:Teichoic Acids